181 related articles for article (PubMed ID: 8752138)
21. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
22. Differentiation induces pituitary adenylate cyclase-activating polypeptide receptor expression in PC-12 cells.
Cavallaro S; D'Agata V; Guardabasso V; Travali S; Stivala F; Canonico PL
Mol Pharmacol; 1995 Jul; 48(1):56-62. PubMed ID: 7623775
[TBL] [Abstract][Full Text] [Related]
23. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
J Mol Neurosci; 2003 Apr; 20(2):153-62. PubMed ID: 12794309
[TBL] [Abstract][Full Text] [Related]
24. Characterization of ocular receptors for pituitary adenylate cyclase activating polypeptide (PACAP) and their coupling to adenylate cyclase.
Nilsson SF; De Neef P; Robberecht P; Christophe J
Exp Eye Res; 1994 Apr; 58(4):459-67. PubMed ID: 7925682
[TBL] [Abstract][Full Text] [Related]
25. Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung.
Busto R; Carrero I; Guijarro LG; Solano RM; Zapatero J; Noguerales F; Prieto JC
Am J Physiol; 1999 Jul; 277(1):L42-8. PubMed ID: 10409229
[TBL] [Abstract][Full Text] [Related]
26. [Pituitary adenylate cyclase-activating polypeptide].
Gonzalez BJ; Basille M; Vaudry D; Fournier A; Vaudry H
Ann Endocrinol (Paris); 1998 Dec; 59(5):364-405. PubMed ID: 9949891
[TBL] [Abstract][Full Text] [Related]
27. The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK.
Cauvin A; Buscail L; Gourlet P; De Neef P; Gossen D; Arimura A; Miyata A; Coy DH; Robberecht P; Christophe J
Peptides; 1990; 11(4):773-7. PubMed ID: 2172943
[TBL] [Abstract][Full Text] [Related]
28. Specific antibody recognition of rat pituitary adenylate cyclase activating polypeptide receptors.
Li M; Shioda S; Somogyvári-Vigh A; Onda H; Arimura A
Endocrine; 1997 Oct; 7(2):183-90. PubMed ID: 9549044
[TBL] [Abstract][Full Text] [Related]
29. Continuous activation of pituitary adenylate cyclase-activating polypeptide receptors elicits antipodal effects on cyclic AMP and inositol phospholipid signaling pathways in CATH.a cells: role of protein synthesis and protein kinases.
Muller A; Lutz-Bucher B; Kienlen-Campard P; Koch B; Loeffler JP
J Neurochem; 1998 Apr; 70(4):1431-40. PubMed ID: 9523559
[TBL] [Abstract][Full Text] [Related]
30. Cyclic lactam analogues of ovine pituitary adenylate cyclase activating polypeptide (PACAP): discovery of potent type II receptor antagonists.
Bitar KG; Somogyvari-Vigh A; Coy DH
Peptides; 1994; 15(3):461-6. PubMed ID: 7937320
[TBL] [Abstract][Full Text] [Related]
31. Pituitary adenylate cyclase-activating polypeptide triggers dual transduction signaling in CATH.a cells and transcriptionally activates tyrosine hydroxylase and c-fos expression.
Muller A; Monnier D; Rene F; Larmet Y; Koch B; Loeffler JP
J Neurochem; 1997 Apr; 68(4):1696-704. PubMed ID: 9084443
[TBL] [Abstract][Full Text] [Related]
32. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta.
Scaldaferri ML; Modesti A; Palumbo C; Ulisse S; Fabbri A; Piccione E; Frajese G; Moretti C
Endocrinology; 2000 Mar; 141(3):1158-67. PubMed ID: 10698193
[TBL] [Abstract][Full Text] [Related]
33. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors.
Robberecht P; Woussen-Colle MC; Vertongen P; De Neef P; Hou X; Salmon I; Brotchi J
Peptides; 1994; 15(4):661-5. PubMed ID: 7937342
[TBL] [Abstract][Full Text] [Related]
34. Addition of the (28-38) peptide sequence of PACAP to the VIP sequence modifies peptide selectivity and efficacy.
Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Robberecht P
Int J Pept Protein Res; 1996 Oct; 48(4):391-6. PubMed ID: 8919060
[TBL] [Abstract][Full Text] [Related]
35. Pituitary adenylate cyclase-activating polypeptide activates different signal transducing mechanisms in cultured cerebellar granule cells.
Favit A; Scapagnini U; Canonico PL
Neuroendocrinology; 1995 Apr; 61(4):377-82. PubMed ID: 7783851
[TBL] [Abstract][Full Text] [Related]
36. Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J.
Buscail L; Gourlet P; Cauvin A; De Neef P; Gossen D; Arimura A; Miyata A; Coy DH; Robberecht P; Christophe J
FEBS Lett; 1990 Mar; 262(1):77-81. PubMed ID: 2156735
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Ciccarelli E; Svoboda M; De Neef P; Di Paolo E; Bollen A; Dubeaux C; Vilardaga JP; Waelbroeck M; Robberecht P
Eur J Pharmacol; 1995 Feb; 288(3):259-67. PubMed ID: 7774670
[TBL] [Abstract][Full Text] [Related]
38. Pituitary adenylate cyclase activating polypeptide-mediated intracrine signaling in the testicular germ cells.
Li M; Funahashi H; Mbikay M; Shioda S; Arimura A
Endocrine; 2004 Feb; 23(1):59-75. PubMed ID: 15034198
[TBL] [Abstract][Full Text] [Related]
39. PACAP-preferring receptors in human hyperplastic prostate.
Carmena MJ; Solano RM; Guijarro LG; Prieto JC
Ann N Y Acad Sci; 1996 Dec; 805():708-12. PubMed ID: 8993465
[No Abstract] [Full Text] [Related]
40. Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas.
Vertongen P; Devalck C; Sariban E; De Laet MH; Martelli H; Paraf F; Hélardot P; Robberecht P
J Cell Physiol; 1996 Apr; 167(1):36-46. PubMed ID: 8698838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
